⚕ For healthcare professionals & patients — informational use only, not a substitute for medical advice. 15,548 products indexed

LETROZOLE

LETROZOLE · by SHAIGAN

ENDOCRINE HORMONE THERAPY Non-steroidal aromatase inhibitor SHAIGAN

Composition

Tab:Letrozole 2.5 mg.

Indications & Dosage

First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer, Adjuvant treatment of oestrogen-receptor-positive invasive early breast cancer in postmenopausal women, Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years, Neo-adjuvant treatment in postmenopausal women with localized hormone-receptor-positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated: Adult: 2.5 mg daily.

Contraindications

Pre-menopausal women, very severe hepatic impairment.

Precautions

Very severe renal impairment.Susceptibility to osteoporosis

Pregnancy

Positive evidence of risk: Avoid

Lactation

Contraindicated. Discontinue breast-feeding

Side Effects

Alopecia, anorexia, appetite increase, arthralgia, bone fracture, constipation, depression, diarrhoea, dizziness, dry skin, dyspepsia, fatigue, headache, hot flushes, hypercholesterolaemia, hypertension, increased sweating, musculoskeletal pain, nausea, osteoporosis, peripheral oedema, rash, vaginal bleeding, vomiting, weight changes, anxiety, arthritis, blurred vision, breast pain, cardiac events, cataract, cerebrovascular events, cough, dysaesthesia, dyspnea, leucopenia, memory impairment, mucosal dryness, palpitation, pruritus, pyrexia, stomatitis, tachycardia, thrombophlebitis, tumour, urinary frequency, urinary-tract infection, urticaria, hepatitis, toxic epidermal necrolysis. Rare Arterial thrombosis, pulmonary embolism